| clinical trial | Q30612 |
| P3098 | ClinicalTrials.gov ID | NCT04418427 |
| P6099 | clinical trial phase | phase II clinical trial | Q42824440 |
| P17 | country | United States of America | Q30 |
| P582 | end time | 2021-05-01 | |
| P921 | main subject | diabetic retinopathy | Q631361 |
| eye disease | Q3041498 | ||
| diabetic macular edema | Q18558081 | ||
| Gene Therapy | Q57136618 | ||
| P1050 | medical condition | diabetic retinopathy | Q631361 |
| P2899 | minimum age | 18 | |
| P1132 | number of participants | 33 | |
| P8005 | research subject recruitment status | recruiting | Q76649708 |
| P1813 | short name | INFINITY | |
| P580 | start time | 2020-05-28 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | A Phase 2, Multi-Center, Randomized, Double-Masked, Active Controlled Study of ADVM-022 (AAV.7m8-aflibercept) in Subjects With Diabetic Macular Edema [INFINITY] |
Search more.